Lung Cancer

Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer

By Phoebe Starr

Lung Cancer, Solid Tumors, Personalized Medicine

August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights

Chicago, IL—Alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, was called a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer (NSCLC), based on results of the phase 3 ALEX clinical trial, which were presented at the 2017 ASCO annual meeting.

Highlights from Best Practices in Lung Cancer Navigation Summit

Highlights from Best Practices in Lung Cancer Navigation Summit

At the Best Practices in Lung Cancer Navigation Summit, held October 22, 2016, in Rosemont, IL, oncology nurse navigators involved in the care of patients with lung cancer convened to discuss the complexities and role of nurse navigators in the treatment of lung cancer.

Challenges in Managing Toxicities

Challenges in Managing Toxicities

By Dr. Edward Garon

Lung Cancer, WCLC 2016 – Lung Cancer

Dr. Edward Garon believes it's important to recognize that agents without efficacy are not beneficial to the patient despite low toxicity.

My Practice: Roles and Responsibilities

My Practice: Roles and Responsibilities

By Dr. Edward Garon

Lung Cancer, WCLC 2016 – Lung Cancer

Dr. Edward Garon describes how staff at his practice interacts with patients.

Immunotherapies and Lung Cancer

Immunotherapies and Lung Cancer

By Dr. Edward Garon

Lung Cancer, WCLC 2016 – Lung Cancer

Dr. Edward Garon explains how he discusses immunotherapies with patients.

Choosing the Right Therapy for Patients with NSCLC

Choosing the Right Therapy for Patients with NSCLC

By Dr. Edward Garon

Lung Cancer, WCLC 2016 – Lung Cancer

Dr. Edward Garon shares an anecdote about an interesting NSCLC case from his practice.

Differences in NSCLC Patient Populations

Differences in NSCLC Patient Populations

By Dr. Edward Garon

Lung Cancer, WCLC 2016 – Lung Cancer

Dr. Edward Garon speaks about how differences in patient populations with lung cancer can make it difficult to interpret and act on data.

ALK Gene Rearrangement and PD-L1 Expression

ALK Gene Rearrangement and PD-L1 Expression

By Dr. Edward Garon

Lung Cancer, WCLC 2016 – Lung Cancer

Dr. Edward Garon does not believe there is much value in utilizing PD-L1 inhibitors for pateints with ALK gene rearrangement.

A Look at PD-1 and PD-L1 Inhibitors

A Look at PD-1 and PD-L1 Inhibitors

By Dr. Edward Garon

Lung Cancer, WCLC 2016 – Lung Cancer

Dr. Edward Garon discusses the use of PD-1 and PD-L1 inhibitors in patients with lung cancer.

Shifts in Lung Cancer Treatment

Shifts in Lung Cancer Treatment

By Dr. Edward Garon

Lung Cancer, WCLC 2016 – Lung Cancer

Dr. Edward Garon reviews how certain drugs can change the landscape for treating patients with lung cancer.

Page 6 of 9

3
4
5
6
7
8
9